ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 173 filers reported holding ACCELERON PHARMA INC in Q3 2018. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $3,442,000 | +623.1% | 20,000 | +300.0% | 0.05% | +487.5% |
| Q2 2020 | $476,000 | -94.0% | 5,000 | -96.7% | 0.01% | -95.5% |
| Q4 2019 | $7,953,000 | +11.8% | 150,000 | -16.7% | 0.18% | -9.7% |
| Q3 2019 | $7,112,000 | -13.4% | 180,000 | -10.0% | 0.20% | +4.3% |
| Q2 2019 | $8,216,000 | -4.6% | 200,000 | +8.1% | 0.19% | +69.4% |
| Q1 2019 | $8,615,000 | +19.9% | 185,000 | +12.1% | 0.11% | +15.6% |
| Q4 2018 | $7,186,000 | +4.6% | 165,000 | +37.5% | 0.10% | +12.9% |
| Q3 2018 | $6,868,000 | -5.6% | 120,000 | -20.0% | 0.08% | -16.7% |
| Q2 2018 | $7,278,000 | +3.4% | 150,000 | -16.7% | 0.10% | -30.1% |
| Q1 2018 | $7,038,000 | -7.9% | 180,000 | 0.0% | 0.15% | -11.0% |
| Q4 2017 | $7,639,000 | -3.7% | 180,000 | -15.3% | 0.16% | -16.8% |
| Q3 2017 | $7,931,000 | +117.5% | 212,500 | +77.1% | 0.20% | +169.9% |
| Q2 2017 | $3,647,000 | +236.1% | 120,000 | +192.7% | 0.07% | +386.7% |
| Q1 2017 | $1,085,000 | – | 41,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 917,767 | $52,524,000 | 8.19% |
| Foresite Capital Management II, LLC | 220,268 | $12,606,000 | 4.66% |
| Foresite Capital Management III, LLC | 250,863 | $14,357,000 | 3.17% |
| Novo Holdings A/S | 650,000 | $37,200,000 | 2.95% |
| QVT Financial LP | 190,977 | $10,930,000 | 2.82% |
| Perceptive Advisors | 1,528,205 | $87,459,000 | 2.34% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,117,651 | $63,963,000 | 2.29% |
| Asymmetry Capital Management, L.P. | 39,912 | $2,284,000 | 2.11% |
| SECTORAL ASSET MANAGEMENT INC | 298,726 | $17,096,000 | 1.82% |
| Stanley-Laman Group, Ltd. | 125,020 | $7,155,000 | 1.76% |